NCT05438420 2026-02-24Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid TumorsQurient Co., Ltd.Phase 1/2 Active not recruiting120 enrolled
NCT03329950 2024-03-28A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex TherapeuticsPhase 1 Completed132 enrolled
NCT03544723 2020-06-09Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.MultiVir, Inc.Phase 2 Unknown40 enrolled